Announcement • Jul 21
Sirnaomics Ltd. Announces Establishment of External Scientific Advisory Board
Sirnaomics Ltd. had established an external Scientific Advisory Board (SAB) on July 21, 2026 to provide independent, authoritative scientific guidance for the Group’s therapeutic pipeline research and development programs. The SAB comprised five internationally renowned multidisciplinary experts with in-depth expertise covering RNA delivery technology, RNAi drug discovery, oncology research and development (R&D), clinical translational medicine, Chemistry, Manufacturing, and Controls (CMC) activities, and global pharmaceutical regulatory compliance. Dr. David Evans, Ph.D., co-founder of the Company and core developer of the Group’s polypeptide nanoparticle (PNP) delivery platform, brought over 30 years of specialized experience in RNA mechanism research and novel drug discovery. Dr. David Evans earned his B.Sc. (Hons) and Ph.D. in Biochemistry from Imperial College London and completed postdoctoral fellowships at the University of Maryland and St. Louis University School of Medicine. Dr. Dmitry Samarsky, Ph.D., distinguished specialist in oligonucleotide therapeutics, former Chief Technology Officer of the Company and inventor of the proprietary GalAhead™ delivery platform, had expertise in novel delivery system iteration and optimization. Dr. Dmitry Samarsky earned his Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts and conducted post-doctoral training at UMass Medical School as an H. Arthur Smith Fellow. Dr. Johnson Yiu-Nam Lau, MBBS, MD, FRCP, FHKCP, FHKAM, seasoned physician and biotech executive, had extensive experience in securing regulatory approvals for multiple novel drugs from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Therapeutic Goods Administration (TGA), along with deep insights into biotech capital operations and commercial product management. Dr. Johnson Yiu-Nam Lau earned his medical degrees (MBBS, MD) from the University of Hong Kong and is a Fellow of the Royal College of Physicians (London), the Hong Kong Academy of Medicine and the Hong Kong College of Physicians. Dr. Archie Tse, M.D., Ph.D., President, Head of Research & Development at Adlai Nortye, senior executive leader in oncology R&D, had distinguished experience working at Merck, Daiichi-Sankyo and CStone Pharmaceuticals, specializing in the research and industrial transformation of small-molecule drugs, monoclonal antibodies, ADCs and tumor vaccines. Dr. Archie Tse earned his Doctor of Medicine, Doctor of Biochemistry and Molecular Biology degrees from the University of Southern California. Dr. Audrey Jia, M.D., Ph.D., former senior CMC reviewer at the FDA, possessed authoritative expertise in global cross-border regulatory strategies for Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) filings, as well as end-to-end Good Manufacturing Practice (GMP) compliance management. Dr. Audrey Jia trained as a medical professional at Peking University before earning her Ph.D. at Emory University and master’s degree in Regulatory Affairs at Johns Hopkins University. She is certified by the Educational Commission for Foreign Medical Graduates (ECFMG) and has passed the United States Medical Licensing Examination (USMLE).
